Core Viewpoint - Multiple listed companies have announced substantial cash dividends for the fiscal year 2025, reflecting strong financial performance and a commitment to returning value to shareholders [2][3][4]. Financial Performance Summary - Farah Electronics reported a revenue of 5.327 billion yuan, an increase of 11.64% year-on-year, and a net profit of 1.192 billion yuan, up 14.72% [2]. - The company plans to distribute a cash dividend of 23 yuan per 10 shares, totaling 517.5 million yuan, which represents 43.41% of its net profit [2]. - Xinhua Insurance plans to distribute a cash dividend of 2.06 yuan per share, totaling 6.426 billion yuan, based on a total share count of 3.1195 billion [3]. - New Hope Co. intends to distribute 9.60 yuan per 10 shares, amounting to 2.97 billion yuan [4]. - Transsion Holdings will distribute 9.00 yuan per 10 shares, totaling 1.036 billion yuan, which is 40.15% of its net profit [4]. Dividend Distribution Plans - Jiepte plans to distribute 8.90 yuan per 10 shares, totaling approximately 84.37 million yuan, which is 30.26% of its net profit [4]. - Hualan Biological plans to distribute 8.00 yuan per 10 shares, totaling 476 million yuan [4]. - Donghang Logistics will distribute 6.77 yuan per 10 shares, totaling 1.075 billion yuan, which is 40% of its net profit [5]. - Jiangling Motors plans to distribute 5.5581 yuan per 10 shares, totaling 475 million yuan [7]. - Huazhong Heavy Industry plans to distribute 5.12 yuan per 10 shares, totaling 599 million yuan [8]. Additional Companies Announcing Dividends - Jingwang Electronics plans to distribute 5.50 yuan per 10 shares [8]. - China Southern Airlines plans to distribute 5.10 yuan per 10 shares, totaling 544 million yuan, which is 58.76% of its net profit [8]. - Galaxy Magnetics plans to distribute 4.00 yuan per 10 shares, totaling 129 million yuan [9]. - Xidian New Energy plans to distribute 4.00 yuan per 10 shares [9].

证券代码：301206 证券简称：三元生物 公告编号：2026-014 关于持股 5%以上股东减持股份的预披露公告 公司持股 5%以上股东吕熙安保证向本公司提供的信息内容真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 山东三元生物科技股份有限公司 持有山东三元生物科技股份有限公司（以下简称"公司"或"三元生物"） 股份 12,852,000 股（占剔除公司回购专用证券账户股份后总股本的 6.4260%）的 股东吕熙安先生，计划自本公告披露之日起 15 个交易日后的 3 个月内（2026 年 4 月 10 日至 2026 年 7 月 9 日）以集中竞价方式减持公司股份不超过 1,000,000 股（即不超过剔除公司回购专用证券账户股份后总股本的 0.5%）。 公司于近日收到持股 5%以上股份的股东吕熙安先生出具的《股份减持计划 告知函》，现将有关情况公告如下： 一、股东的基本情况 | 股东名称 | 持股数量（股） | 占公司当前总股本比例 | | --- | --- | --- | | 吕熙安 | 12,852,000 | ...

证券代码：301206 证券简称：三元生物 公告编号：2026-013 山东三元生物科技股份有限公司 关于股东减持股份的预披露公告 公司股东山东鲁信祺晟投资管理有限公司-山东省鲁信资本市场发展股权投 资基金合伙企业（有限合伙）保证向本公司提供的信息内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 二、本次减持计划的主要内容 （一）减持原因：公司经营发展需求。 （二）股份来源：首次公开发行前取得的股份及上市后以资本公积金转增股 本方式取得的股份。 （三）减持股份数量及比例：本次拟减持股份数量合计不超过 1,930,000 股， 即不超过剔除公司回购专用证券账户股份后总股本的 0.97%。 持有山东三元生物科技股份有限公司（以下简称"公司"或"三元生物"） 股份 1,930,000 股（占剔除公司回购专用证券账户股份后总股本的 0.97%）的股 东山东鲁信祺晟投资管理有限公司-山东省鲁信资本市场发展股权投资基金合伙 企业（有限合伙）（以下简称"鲁信资本"），计划自本公告披露之日起 15 个交 易日后的 3 个月内（2026 ...

Group 1 - The stock price of Sanyuan Bio (301206.SZ) fell by 4.07% to 28.55 yuan as of the market close on February 27 [1] - Sanyuan Bio was listed on the Shenzhen Stock Exchange's ChiNext board on February 10, 2022, with an initial public offering (IPO) of 33.721 million shares at a price of 109.30 yuan per share [1][2] - On its first trading day, Sanyuan Bio reached a peak price of 146.00 yuan, but is currently in a state of decline [2] Group 2 - The total funds raised from the IPO amounted to 3.686 billion yuan, with a net amount of 3.547 billion yuan after deducting issuance costs [2] - The net funds raised exceeded the original plan by 2.647 billion yuan, as the company initially aimed to raise 900 million yuan for various projects [2] - The total issuance costs for the IPO were 139 million yuan, including 121 million yuan for underwriting and sponsorship fees [3] Group 3 - In 2021, Sanyuan Bio announced a dividend distribution plan, distributing 10 yuan in cash per 10 shares (including tax) and a bonus of 5 shares for every 10 shares held [3] - The total share capital before the dividend distribution was 135 million shares, which increased to 202 million shares after the distribution [3] - The record date for the dividend distribution was June 16, 2022, and the ex-dividend date was June 17, 2022 [3]

证券代码：301206 证券简称：三元生物 公告编号：2026-012 山东三元生物科技股份有限公司 1 / 4 关于部分募集资金专户销户完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）于深圳证券交易所创 业板首次公开发行股票募集资金按照相关法律、法规及规范性文件的规定在银行 开立了募集资金专用账户。近日，公司募集资金专用账户的注销手续已经办理完 成，现将具体情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意山东三元生物科技股份有限公司首次 公开发行股票注册的批复》（证监许可【2021】4073 号）核准，并经深圳证券 交易所同意，公司向社会公众公开发行人民币普通股（A 股）3,372.10 万股，每 股面值为人民币 1.00 元，发行价格为人民币 109.3 元/股，募集资金总额为人民 币 368,570.53 万元。扣除承销费和其他发行费用，募集资金净额为人民币 354,664.46 万元，上述募集资金到位情况业经上会会计师事务所（特殊普通合伙） 以"上会师报字【2022】第 ...

Group 1 - The core viewpoint of the article highlights a short-term surge in A-share sugar substitute concept stocks, with Baolingbao hitting the daily limit, and companies like Sanyuan Bio, Jinhui Industrial, and Huakang Co. also experiencing gains [1] Group 2 - Baolingbao reached the daily limit, indicating strong investor interest and confidence in the sugar substitute sector [1] - Sanyuan Bio, Jinhui Industrial, and Huakang Co. followed suit with notable increases in their stock prices, reflecting a broader trend in the market [1]

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于山东三元生物科技股份有限公司 2026 年第一次临时股东会的 法律意见书 国枫律股字[2026]A0063 号 致：山东三元生物科技股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2026 年第一次临时股东会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律 业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法 律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《山东三元生物科技 股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程 序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形。 证券代码：301206 证券简称：三元生物 公告编号：2026-011 山东三元生物科技股份有限公司 2026 年第一次临时股东会决议公告 5、会议主持人：董事长聂在建 6、会议召开情况的合法、合规性说明：本次会议的召集、召开与表决程序 符合《公司法》《深圳证券交易所创业板股票上市规则》及《公司章程》的有关 规定，所作决议合法有效。 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 现场会议时间：2026 年 2 月 24 日（星期二）15:00 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为： 2026 年 2 月 24 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳证券交易 所互联网投票系统的具体时间为：2026 年 2 月 24 日 9:15 至 15:00 2、会议召开地点：山东省滨州市滨北梧桐十路 101 号三元生物公司会议室 3、会议召 ...

Core Viewpoint - Sanyuan Biotech is facing multiple dynamics including the final ruling of anti-dumping duties in the U.S., progress on the allulose project, and the promotion of new products [1] Group 1: Stock Recent Trends - The U.S. Department of Commerce has announced a final ruling on anti-dumping and countervailing investigations regarding Chinese erythritol products, with Sanyuan Biotech facing a comprehensive execution tax rate of 93.58% for exports to the U.S. This ruling will take effect upon publication in the Federal Register and may have a lasting impact on the company's U.S. market operations [2] - The European Union will impose a 156.7% anti-dumping tax on Chinese erythritol starting January 2025, lasting for five years. The company has responded by launching blended products, indicating that the impact of this event may persist [2] Group 2: Company Project Progress - The company's annual production project for 20,000 tons of allulose has completed the construction of the main engineering and equipment installation for the remaining 10,000 tons of capacity. The next steps will involve organizing environmental assessments and gradually advancing production. This project aims to enrich the product portfolio, but the production schedule and benefits are subject to approval processes and market demand [3] Group 3: Business Development Status - Sanyuan Biotech is continuously providing samples of Reb M to domestic and international potential customers and conducting application experiments. Some customers have already incorporated it into their reduced-sugar product formulations. Tagatose, as a key new functional sugar, is in a critical phase of market promotion and industrial application [4] Group 4: Company Status - The company will hold a board meeting on February 4, 2026, to review the proposal for convening the first extraordinary shareholders' meeting of 2026, with further arrangements to be announced [5]

Core Viewpoint - San Yuan Bio announced that as of February 10, 2026, the company has a total of 15,658 registered shareholders [2] Company Summary - The company is actively engaging with investors through interactive platforms, indicating a focus on transparency and communication [2] - The number of registered shareholders reflects the company's growth and potential interest from the investment community [2]